More than 5.3 million people are currently diagnosed with Alzheimer’s disease in the United States, and that number is expected to double by 2030. The global costs of the disease are estimated at $604 billion, or 1 percent of global GDP. Despite this looming crisis, no definitive, early means of diagnosis or successful treatment exists today. This prize development effort focuses on two key areas — screening and treatments — to catalyze breakthroughs that will enable early patient targeting and effective delivery of treatment and care.
Two potential prize concepts have arisen from prize development work in Alzheimer’s focusing on screening and treatment. The winning team will:
- The winning team will develop the means to effectively and scalably screen patients at risk for Alzheimer’s disease.
- The winning team will demonstrate the ability to improve cognitive function in late stage Alzheimer’s patients.
To find out how you can help support this XPRIZE, please email [email protected].